Skip to main content

Table 3 Combination of current ELN risk classification with TriAS leads to a refined ELN + TriAS classification showing three groups with adverse (≤25 %), intermediate (50–60 %), and favorable (>60 %) survival after 3 years

From: A three-gene expression-based risk score can refine the European LeukemiaNet AML classification

ELN risk

TriAS

Number of patients

3-year OS (%)

Median OS (days)

Refined ELN + TriAS

Favorable

1

24

77.4

Not reached

Favorable

Favorable

2

59

75.4

3555

Favorable

Intermediate 1/2

1

7

68.6

Not reached

Favorable

Favorable

3

46

58.1

1805

Intermediate

Favorable

4

12

52.1

Not reached

Intermediate

Intermediate 1/2

2

54

50.9

1193

Intermediate

Adverse

1

2

50.0

Not reached

Intermediate

Intermediate 1/2

3

78

25.6

366

Adverse

Intermediate 1/2

4

22

23.9

214

Adverse

Adverse

2

24

21.4

368

Adverse

Adverse

3

30

18.2

347

Adverse

Adverse

4

17

0.0

214

Adverse